Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC

被引：0
|
作者：
Van Zandwijk, N [1 ]
Baas, P [1 ]
机构：
[1] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
来源：
TUMORI | 2002年
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S37 / S38
页数：2
相关论文
共 50 条
  • [21] Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR plus NSCLC
    Nagasaka, Misako
    Zhu, Viola W.
    Lim, Sun Min
    Greco, Michael
    Wu, Fengying
    Ou, Sai-Hong Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) : 740 - 763
  • [22] USE PATTERNS OF FIRST-LINE INHIBITORS OF TYROSINE KINASE AND TIME TO CHANGE TO SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
    Machado-Alba, J.
    Machado-Duque, M.
    VALUE IN HEALTH, 2017, 20 (05) : A93 - A93
  • [23] Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
    Helena Linardou
    Issa J. Dahabreh
    Dimitrios Bafaloukos
    Paris Kosmidis
    Samuel Murray
    Nature Reviews Clinical Oncology, 2009, 6 : 352 - 366
  • [24] A new generation of EGFR tyrosine-kinase inhibitors in NSCLC
    Hirsch, Fred R.
    Bunn, Paul A., Jr.
    LANCET ONCOLOGY, 2012, 13 (05): : 442 - 443
  • [25] Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
    Linardou, Helena
    Dahabreh, Issa J.
    Bafaloukos, Dimitrios
    Kosmidis, Paris
    Murray, Samuel
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (06) : 352 - 366
  • [26] Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells
    Jin, Hyeon-Ok
    Hong, Sung-Eun
    Kim, Chang Soon
    Park, Jin-Ah
    Kim, Jin-Hee
    Kim, Ji-Young
    Kim, Bora
    Chang, Yoon Hwan
    Hong, Seok-Il
    Hong, Young Jun
    Park, In-Chul
    Lee, Jin Kyung
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2015, 287 (01) : 17 - 25
  • [27] Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors
    Lipton, J. H.
    Bryden, P.
    Sidhu, M. K.
    Huang, H.
    McGarry, L. J.
    Lustgarten, S.
    Mealing, S.
    Woods, B.
    Whelan, J.
    Hawkins, N.
    LEUKEMIA RESEARCH, 2015, 39 (01) : 58 - 64
  • [28] Impact of Second-Generation Tyrosine Kinase Inhibitors As Second Line Treatment for Patients with Chronic Myeloid Leukemia
    Valentin Garcia-Gutierrez, J.
    Herrera, Pilar
    Abalo, Lorena L.
    Dolores Rey, Maria
    Calbacho, Maria
    Ramos, Lourdes
    Ramos, Paloma
    Montalban, Carlos
    Lopez-Jimenez, Javier
    BLOOD, 2011, 118 (21) : 1615 - 1615
  • [29] Chronic Myeloid Leukemia Therapy: Focus on Second-Generation Tyrosine Kinase Inhibitors
    McFarland, K. Leigh
    Wetzstein, Gene A.
    CANCER CONTROL, 2009, 16 (02) : 132 - 140
  • [30] Second-Line Therapy for Advanced NSCLC
    Weiss, Jared M.
    Stinchcombe, Thomas E.
    ONCOLOGIST, 2013, 18 (08): : 947 - 953
12345